Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America

Imagem de Miniatura
Arquivos
art_APIQUIAN_Clinical_outcomes_of_longacting_injectable_risperidone_in_patients_2011.PDF (349 KB)
Citações na Scopus
12
Tipo de produção
article
Data de publicação
2011
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
DOVE MEDICAL PRESS LTD
Autores
APIQUIAN, Rogelio
CORDOBA, Rodrigo
Citação
NEUROPSYCHIATRIC DISEASE AND TREATMENT, v.7, p.19-26, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Risperidone long-acting injection (RLAI) has been shown to be efficacious, improve compliance, and increase long-term retention rate on therapy. The aim of this work was to determine the effect of RLAI on clinical outcome and hospitalization rate in patients with schizophrenia or schizoaffective disorder enrolled in the electronic Schizophrenia Treatment Adherence Registry in Latin America. Methods: Data were collected at baseline, retrospectively for the 12 months prior to baseline, and prospectively every three months for 24 months. Hospitalization prior to therapy was assessed by a retrospective chart review. Efficacy and functioning were evaluated using Clinical Global Impression of Illness Severity (CGI-S), Personal and Social Performance (PSP), and Global Assessment of Functioning (GAF) scores. Relapse and treatment were also registered. Results: Patients were recruited in Mexico (n = 53), Brazil (n = 11), and Colombia (n = 15). Sixty-five percent (n = 52) were male, and mean age was 32.9 years. Patients were classified as having schizophrenia (n = 73) or schizoaffective disorder (n = 6). The mean dose of RLAI at six months was 34.1 mg (standard deviation = 10.2 mg). The percentage of hospitalized patients before treatment was 28.2% and 5.1% at six months after initiating RLAI (P < 0.001). Significant changes were registered on CGI-S, GAF, and PSP scores. Conclusions: RLAI was associated with an improvement in clinical symptoms and functioning, and a greater reduction in hospitalization.
Palavras-chave
long-acting, risperidone, schizophrenia, schizoaffective disorder, Latin America
URI
https://observatorio.fm.usp.br/handle/OPI/24014
Referências
  1. Annemans L, 2005, PHARMACOECONOMICS, V23, P1
  2. Robinson D, 1999, ARCH GEN PSYCHIAT, V56, P241, DOI 10.1001/archpsyc.56.3.241
  3. Taylor DM, 2009, J CLIN PSYCHIAT, V70, P196
  4. Gilmer TP, 2004, AM J PSYCHIAT, V161, P692, DOI 10.1176/appi.ajp.161.4.692
  5. WRIGHT EC, 1993, LANCET, V342, P909, DOI 10.1016/0140-6736(93)91951-H
  6. Moller HJ, 2005, INT CLIN PSYCHOPHARM, V20, P121
  7. Keefe RSE, 2007, ARCH GEN PSYCHIAT, V64, P633, DOI 10.1001/archpsyc.64.6.633
  8. Leucht S, 2009, LANCET, V373, P31, DOI [10.1016/S0140-6736(08)61764-X, 10.1016/S01406736(08)61764-X]
  9. Lacro JP, 2002, J CLIN PSYCHIAT, V63, P892
  10. Fleischhacker WW, 2003, J CLIN PSYCHIAT, V64, P1250
  11. Wiersma D, 1998, SCHIZOPHRENIA BULL, V24, P75
  12. ENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33, P766
  13. Almond S, 2004, BRIT J PSYCHIAT, V184, P346, DOI 10.1192/bjp.184.4.346
  14. Valenstein M, 2002, MED CARE, V40, P630, DOI 10.1097/01.MLR.0000021003.43524.64
  15. Rosa MA, 2005, REV BRAS PSIQUIATR, V27, P178, DOI 10.1590/S1516-44462005000300005
  16. Goeree R, 2005, CURR MED RES OPIN, V21, P2017, DOI 10.1185/030079905X75087
  17. Olivares JM, 2009, EUR PSYCHIAT, V24, P287, DOI 10.1016/j.eurpsy.2008.12.002
  18. Emsley R, 2008, INT CLIN PSYCHOPHARM, V23, P325, DOI 10.1097/YIC.0b013e32830c2042
  19. Lehman AF, 1998, SCHIZOPHRENIA BULL, V24, P11
  20. WEIDEN P, 1995, PSYCHIATR SERV, V46, P1049
  21. Lieberman JA, 1996, J CLIN PSYCHIAT, V57, P5
  22. LINDENMAYER JP, 1994, J CLIN PSYCHOPHARM, V14, P201
  23. Swartz MS, 2007, AM J PSYCHIAT, V164, P428, DOI 10.1176/appi.ajp.164.3.428
  24. DAVIS JM, 1994, DRUGS, V47, P741, DOI 10.2165/00003495-199447050-00004
  25. Fleischhacker WW, 2003, J CLIN PSYCHIAT, V64, P10
  26. Peuskens J, 2010, CURR MED RES OPIN, V26, P501, DOI 10.1185/03007990903488670
  27. Morosini PL, 2000, ACTA PSYCHIAT SCAND, V101, P323, DOI 10.1111/j.1600-0447.2000.tb10933.x
  28. Robinson DG, 1999, AM J PSYCHIAT, V156, P544
  29. Dolder CR, 2002, AM J PSYCHIAT, V159, P103, DOI 10.1176/appi.ajp.159.1.103
  30. Nasrallah HA, 2005, PSYCHIAT SERV, V56, P273, DOI 10.1176/appi.ps.56.3.273
  31. Emsley R, 2008, J CLIN PSYCHOPHARM, V28, P210, DOI 10.1097/JCP.0b013e318167269d
  32. Beasley CM, 1996, NEUROPSYCHOPHARMACOL, V14, P111, DOI 10.1016/0893-133X(95)00069-P
  33. Kane JM, 2003, AM J PSYCHIAT, V160, P1125, DOI 10.1176/appi.ajp.160.6.1125
  34. Moore A, 2000, BRIT J CLIN PSYCHOL, V39, P287, DOI 10.1348/014466500163293
  35. Barkic J, 2003, COLLEGIUM ANTROPOL, V27, P111
  36. BEBBINGTON PE, 1995, INT CLIN PSYCHOPHARM, V9, P41, DOI 10.1097/00004850-199501005-00008
  37. BLACKWELL B, 1976, BRIT J PSYCHIAT, V129, P513, DOI 10.1192/bjp.129.6.513
  38. Buckley PF, 2004, SCHIZOPHR RES, V66, P143, DOI 10.1016/j.schres.2003.06.001
  39. Chue Pierre, 2007, Neuropsychiatr Dis Treat, V3, P13, DOI 10.2147/nedt.2007.3.1.13
  40. Colonna L, 2000, INT CLIN PSYCHOPHARM, V15, P13, DOI 10.1097/00004850-200015010-00002
  41. Edwards NC, 2005, PHARMACOECONOMICS, V23, P75
  42. Fleischhacker WW, 2005, BRIT J PSYCHIAT, V187, P131, DOI 10.1192/bjp.187.2.131
  43. Haro JM, 2003, ACTA PSYCHIAT SCAN S, V416, P16
  44. Lambert Tim, 2003, J Psychiatr Pract, V9, P252, DOI 10.1097/00131746-200305000-00011
  45. LIEBERMAN JA, 1992, SCHIZOPHRENIA BULL, V18, P351
  46. Lindenmayer Jean-Pierre, 2006, J Psychiatr Pract, V12, P55, DOI 10.1097/00131746-200601000-00009
  47. Lindenmayer JP, 2004, J CLIN PSYCHIAT, V65, P1084
  48. Marcus SC, 2008, SCHIZOPHRENIA BULL, V34, P173, DOI 10.1093/schbul/sbm061
  49. Marder SR, 1998, J CLIN PSYCHIAT, V59, P21
  50. Marinis T De, 2007, Pharmacopsychiatry, V40, P257, DOI 10.1055/s-2007-992140
  51. Martin SD, 2003, CURR MED RES OPIN, V19, P298, DOI 10.1185/030079903125001893
  52. Masand Prakash S, 2006, Curr Clin Pharmacol, V1, P47, DOI 10.2174/157488406775268255
  53. Masand Prakash S, 2009, Prim Care Companion J Clin Psychiatry, V11, P147, DOI 10.4088/PCC.08r00612
  54. Nasrallah HA, 2004, J CLIN PSYCHIAT, V65, P531
  55. Parellada E, 2005, J PSYCHOPHARMACOL, V19, P5, DOI 10.1177/0269881105056513
  56. Patel MX, 2008, J CLIN PSYCHIAT, V69, P1548
  57. Pereira S, 1997, ACTA PSYCHIAT SCAND, V95, P464, DOI 10.1111/j.1600-0447.1997.tb10133.x
  58. Peuskens J, 2002, EUR NEUROPSYCHOPHARM, V12, P305, DOI 10.1016/S0924-977X(02)00031-7
  59. REMINGTON GJ, 1995, CAN J PSYCHIAT, V40, pS5
  60. Schmauss M, 2007, INT CLIN PSYCHOPHARM, V22, P85, DOI 10.1097/YIC.0b013e3280119ddb
  61. SHEPHERD M, 1989, PSYCHOL MED, P1
  62. Turner M, 2004, INT CLIN PSYCHOPHARM, V19, P241, DOI 10.1097/01.yic.0000133500.92025.20
  63. Vehof J, 2008, J CLIN PSYCHOPHARM, V28, P625, DOI 10.1097/JCP.0b013e31818a6d10
  64. Weiden PJ, 2007, J CLIN PSYCHIAT, V68, P12

Coleções
Artigos e Materiais de Revistas Científicas - HC/IPq